Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2024-11-26 AGM Information
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Chairman's Address & Presentations for AGM 27 pages 3.0MB
AGM Information Classification · 95% confidence The document is titled as the Chairman's Address to the Annual General Meeting (AGM) held on 27 November 2024. It contains a detailed speech from the Chairman discussing company milestones, clinical trial progress, financial status, and strategic partnerships. Additionally, there is a company presentation from C14 Consulting Group included, which focuses on business development and licensing strategies. The content is typical of materials shared during an AGM, including updates on company performance, management commentary, and future outlook. There is no indication that this is a full annual report (10-K) or an earnings release (ER), nor is it a proxy statement or voting results announcement. The length (15,000 characters) and detailed nature support it being AGM materials rather than a brief announcement or regulatory filing. Therefore, the document best fits the category of AGM Information (AGM-R).
2024-11-26 English
Results of Annual General Meeting 2 pages 184.9KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement dated 27 November 2024 from Vectus Biosystems Limited regarding the results of their Annual General Meeting (AGM). It details the resolutions voted on, including the re-election of a director and adoption of the remuneration report, and provides voting results. The document references the Corporations Act and ASX Listing Rules, indicating it is a formal announcement of voting outcomes. The length is only 2710 characters, and it does not contain the full AGM materials or presentations, only the voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-11-26 English
Quarterly Activities & Appendix 4C Cash Flow Reports 7 pages 518.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report and Appendix 4C' and references compliance with ASX Listing Rule 4.7B, which pertains to quarterly reports. It includes detailed financial data such as consolidated statements of cash flows, cash on hand, payments to related parties, and commentary on company activities during the quarter ending 30 September 2024. The document also discusses operational updates, clinical trial progress, and financing activities relevant to the quarter. The length and content indicate it is a comprehensive quarterly report containing substantive financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-10-30 English
2024 Notice of AGM & Proxy Form 8 pages 722.1KB
AGM Information Classification · 100% confidence The document is a detailed notice and explanatory notes for the 2024 Annual General Meeting (AGM) of Vectus Biosystems Limited. It includes the date and time of the AGM, instructions for virtual attendance, the agenda including financial statements and reports discussion, resolutions for director re-election and remuneration report adoption, proxy voting instructions, and definitions relevant to the meeting. The document does not contain the actual annual report or financial statements but refers to them and provides a link to the annual report on the company's website. The content is typical of an AGM notice and related materials provided to shareholders to inform them about the meeting and the business to be conducted. Therefore, the document fits the category of AGM Information (AGM-R).
2024-10-27 English
Date of 2024 Annual General Meeting 1 page 147.2KB
AGM Information Classification · 95% confidence The document is a short announcement dated 8 October 2024 from Vectus Biosystems Limited regarding the scheduling of the 2024 Annual General Meeting (AGM). It provides details about the date, time, virtual attendance, and nomination deadline for director elections. It explicitly states that the Notice of Meeting and other AGM information will be issued later. The document does not contain any financial data, detailed presentations, or voting results. It is an announcement about the upcoming AGM rather than the AGM materials themselves. Given the short length (1155 characters) and the nature of the content, this fits the category of AGM Information (AGM-R).
2024-10-07 English
Application for quotation of securities - VBS 7 pages 21.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement used for the application for quotation of securities. It details the issuance and quotation of new securities resulting from the exercise of options or conversion of convertible securities. The document includes specifics about the securities, issue dates, and the nature of the issuance (employee incentive plan). It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement related to capital changes and securities quotation. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is a full announcement, not just a brief notice or certification.
2024-10-06 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.